Apellis adds safety warning to eye therapy

seekingalpha2023-12-01

Apellis Pharmaceuticals (NASDAQ:APLS) lost ~2% in the pre-market Friday after announcing that updated labeling information for its FDA-approved eye disease therapy Syfovre reflects risks related to an...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2388625382?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217908833/image_1217908833.jpg","is_english":true,"pubTime":"2023-12-01 22:18","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2388625382","market":"us","top_or_hot":-1,"title":"Apellis adds safety warning to eye therapy","media":"seekingalpha","content":"<div>\n<p>Apellis Pharmaceuticals (NASDAQ:APLS) lost ~2% in the pre-market Friday after announcing that updated labeling information for its FDA-approved eye disease therapy Syfovre reflects risks related to an...</p>\n\n<a href=\"https://seekingalpha.com/news/4042213-apellis-stock-falls-safety-warning-eye-therapy-syfovre\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis adds safety warning to eye therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis adds safety warning to eye therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-01 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4042213-apellis-stock-falls-safety-warning-eye-therapy-syfovre><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apellis Pharmaceuticals (NASDAQ:APLS) lost ~2% in the pre-market Friday after announcing that updated labeling information for its FDA-approved eye disease therapy Syfovre reflects risks related to an...</p>\n\n<a href=\"https://seekingalpha.com/news/4042213-apellis-stock-falls-safety-warning-eye-therapy-syfovre\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://seekingalpha.com/news/4042213-apellis-stock-falls-safety-warning-eye-therapy-syfovre","article_id":"2388625382","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217908833/image_1217908833.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2388625382","pubTimestamp":1701440307,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Apellis Pharmaceuticals (NASDAQ:APLS) lost ~2% in the pre-market Friday after announcing that updated labeling information for its FDA-approved eye disease therapy Syfovre reflects risks related to an","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","ALPMY":"Astellas Pharma, Inc.","LU0082616367.USD":"摩根大通美国科技A（dist）","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0056508442.USD":"贝莱德世界科技基金A2","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4566":"资本集团","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4573":"虚拟现实","BK4141":"半导体产品","BK4588":"碎股","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","ALPMF":"Astellas Pharma, Inc.","ISEE":"IVERIC bio Inc","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4505":"高瓴资本持仓","BK4007":"制药","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4512":"苹果概念","AMD":"美国超微公司","BK4575":"芯片概念","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4139":"生物科技","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","APLS":"Apellis Pharmaceuticals Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4529":"IDC概念","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD"},"translate_title":"Apellis为眼部治疗增加了安全警告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALPMY":1,"AMD":1,"APLS":1,"ALPMF":1,"ISEE":1},"content_text":"Apellis Pharmaceuticals (NASDAQ:APLS) lost ~2% in the pre-market Friday after announcing that updated labeling information for its FDA-approved eye disease therapy Syfovre reflects risks related to an inflammatory condition called retinal vasculitis. The details about the risk have been added to the “Warnings and Precautions and Adverse Reactions - Postmarketing Experience” sections in the U.S. Prescribing Information of the drug.  In a regulatory filing on Friday, Apellis (APLS) said that the update reflects input from the U.S. FDA, and the cases of retinal vasculitis stood at 0.01% per injection, with over 120K injections used as of November 18, 2023. Early this year, the FDA greenlighted the C3-targeting complement therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a common type of age-related vision loss.  Syfovre competes with Izervay, a complement C5 inhibitor developed by IVERIC bio (ISEE), for the same indication. Japanese drugmaker Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) acquired ISEE for $5.9B in July.    More on Apellis Pharmaceuticals  Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings Apellis Pharmaceuticals reports insider transactions worth $1.9M Apellis Pharmaceuticals falls amid new short call from Citron Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2388625382"}